Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-H5N1 immunoglobulin - Fabentech

Next Previous
Search
Drug Profile

Anti-H5N1 immunoglobulin - Fabentech

Alternative Names: Fabenflu; FBF001

Latest Information Update: 31 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fabentech
  • Developer Fab entech
  • Class Antivirals; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Influenza A virus H5N1 subtype
  • New Molecular Entity No

Highest Development Phases

  • Suspended Influenza A virus H5N1 subtype

Most Recent Events

  • 14 Jul 2017 Suspended - Phase-I for Influenza-A virus H5N1 subtype (In volunteers) in Singapore (Parenteral) (Fabentech communication, July 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(In volunteers) in Singapore (Parenteral, Injection)
  • 12 Oct 2012 Phase-I clinical trials in Influenza-A virus H5N1 subtype (In volunteers) in Singapore (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top